Meropenem Dosing for Gram-Negative Rod Infections
For serious gram-negative rod infections in adults with normal renal function, administer meropenem 1 gram IV every 8 hours as a 30-minute infusion; for Pseudomonas aeruginosa specifically, this same dose is mandatory. 1
Standard Dosing in Normal Renal Function
The FDA-approved dosing for serious gram-negative infections is straightforward 1:
- Complicated intra-abdominal infections: 1 gram IV every 8 hours
- Complicated skin/soft tissue infections: 500 mg IV every 8 hours (standard pathogens) OR 1 gram IV every 8 hours (if P. aeruginosa suspected/confirmed)
- Administration: 15-30 minute infusion (or 3-5 minute bolus for 1 gram doses in adults)
For critically ill patients or those with augmented renal clearance (CrCl ≥90 mL/min), standard dosing is inadequate. Extended infusions (3-4 hours) or continuous infusion should be strongly considered, as these patients frequently achieve subtherapeutic concentrations with conventional dosing 2, 3. The 2017 Surviving Sepsis guidelines emphasize that β-lactam efficacy depends on time above MIC (T>MIC), with 100% T>MIC optimal for severe infections 4.
Renal Dose Adjustments
Dose reduction is mandatory in renal impairment 1, 5, 6:
| Creatinine Clearance | Dose | Interval |
|---|---|---|
| >50 mL/min | Full dose (500 mg or 1 g) | Every 8 hours |
| 26-50 mL/min | Full dose | Every 12 hours |
| 10-25 mL/min | Half dose | Every 12 hours |
| <10 mL/min | Half dose | Every 24 hours |
The terminal half-life increases from ~1 hour in normal renal function to 9-14 hours in anuric patients 5, 6. Meropenem clearance correlates linearly with creatinine clearance 5.
Dialysis Considerations
- Intermittent hemodialysis: Approximately 50% of meropenem is removed during a 4-hour session 6. Administer the dose after dialysis.
- Continuous renal replacement therapy (CRRT): 25-50% removal with CVVHF, 13-53% with CVVHDF 6. Higher doses may be needed; consider therapeutic drug monitoring.
Critical Dosing Pitfalls
The most common error is underdosing patients with preserved or augmented renal clearance. Research demonstrates that patients with CrCl 60-90 mL/min require 6 g/day total to achieve adequate MIC coverage, and those with CrCl ≥90 mL/min need either increased dose/frequency or extended/continuous infusion 2. Standard regimens achieve only 82-85% target attainment for Acinetobacter species even with dose adjustment 7.
For carbapenem-resistant Enterobacterales (CRE) or difficult-to-treat resistant organisms, meropenem monotherapy is inappropriate unless MIC ≤8 mg/L 8, 9, 10. The 2022 ESCMID guidelines and 2024 IDSA guidance recommend newer β-lactam/β-lactamase inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam) as preferred agents for CRE 8, 10.
Pharmacodynamic Optimization
Extended infusions (3-4 hours) maximize time above MIC, particularly important when treating organisms with MIC 2-8 mg/L 4, 11, 2. The 2015 ICU task force on Acinetobacter recommends 2 grams every 8 hours as a 4-hour infusion for strains with MIC ≤8 mg/L 11.
Loading doses are not standard for meropenem (unlike vancomycin or colistin), but critically ill patients with septic shock benefit from immediate full-dose administration without delay 4.
Monitoring Requirements
Therapeutic drug monitoring is not routinely available for meropenem but should be considered in:
- Augmented renal clearance
- CRRT patients
- Treatment failure despite appropriate organism susceptibility
- Infections with pathogens at upper MIC limits (2-8 mg/L)
Target trough concentrations of 8-16 mg/L correlate with optimal outcomes 3.
Pediatric Considerations
For children ≥3 months with normal renal function 1:
- Complicated skin/soft tissue: 10 mg/kg every 8 hours (max 500 mg); 20 mg/kg every 8 hours for P. aeruginosa (max 1 gram)
- Intra-abdominal infections: 20 mg/kg every 8 hours (max 1 gram)
- Meningitis: 40 mg/kg every 8 hours (max 2 grams)
Infusion duration: 15-30 minutes. No pediatric renal dosing data exist in the FDA label; consultation with pediatric infectious diseases is recommended 12.